Image

Lupus Nephritis

Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.

 

Know more with
AVISE® SLE Monitor

The most advanced assessment available

With a powerful combination of biomarkers that go beyond standard SLE tests, AVISE® SLE Monitor empowers you with the full intel to stay a step ahead of flare ups, regularly monitor disease progression, assess treatment efficacy, and help prevent premature disease advancement and long-term damage.

Image

A more advanced assessment requires a more comprehensive biomarker suite

AVISE SLE Monitor

Organ involvement

PC4d Powered by CB-CAPs
Anti-C1q

Disease Activity

Soluble C3/C4
Anti-dsDNA by CIA
EC4d Powered by CB-CAPs

Optional Add-Ons

Therapeutic drug monitoring

HCQ
MTX

EC4d is informative even when C3/C4 is unchanged

In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.5

22%

Fluctuating C3/C4 Levels

78% EC4d disease correlation independent of C3/C4 levels in this patient group

Chronic Levels

Marginal R2 =7.9% (p <0.001)

ES4d is informative even when C3/C4 is unchanged

In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.

22%

Fluctuating C3/C4 Levels

78% EC4d disease correlation independent of C3/C4 levels in this patient group

Chronic Low or Normal C3/C4 Levels

Marginal R2 =7.9% (p <0.001)

Image

Superior detection of organ involvement

PC4d: Detect the potential for thrombosis

Our patented CB-CAPs PC4d test has a strong association with a history of thrombosis and risk for ischemic stroke independent of antiphospholipid antibody levels.

Percent of SLE patients with Thrombosis by PC4d status2

30%

PC4d positive

5%

PC4d negative

Anti-C1q: Identify the risk of Lupus Nephritis

Anti-C1q is superior to other biomarkers in association with SELENA-SLEDAI values and lupus nephritis. SLE patients with positive levels are 2X more likely to have renal involvement.

Percent of patients with increased biomarker levels during high disease activity4

35-44% C3/C4
50% Anti-dsDNA
63% Anti-C1q

Superior detection of changes in disease activity

EC4d: More accurate monitoring

Our proprietary CB-CAPs EC4d test has strong correlation with disease activity and levels decline rapidly with clinical improvement.5

Anti-dsDNA by CIA: Superior accuracy

Chemiluminescence immunoassay (CIA) has expanded dynamic range and demonstrated superior agreement with the Farr assay.1

Superior detection of Lupus Nephritis

EC4d and anti-C1q significantly correlate with decreases in proteinuria observed prospectively—importantly, EC4d had a stronger correlation with uPCR than conventional serum C3/C4.1

Anti-C1q antibodies are significantly associated (OR = 3.2, p < 0.01) with LN independent of demographic and other serological risk factors.1,3

SLE patients who are simultaneously anti-dsDNA, low complement, and anti-C1q positive are most strongly associated (OR = 14.9, p < 0.01) with LN2.3

You deserve quality test results you can trust.

Take control over your patient’s lupus with regular monitoring. Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.

AVISE SLE Monitor is a specialized SLE Disease Monitoring Test Clinically Proven To Correlate With SLE Disease Activity.

The AVISE SLE Monitor test should be considered any time the condition of a SLE patient is being assessed.

Order your AVISE Testing Starter Kit today!

  • This field is for validation purposes and should be left unchanged.

Clinical Utility: AVISE SLE Monitor Test Report

The AVISE SLE Monitor test should be considered any time the condition of a SLE patient is being assessed.

If the patient is also being monitored with AVISE® HCQ, the AVISE SLE Monitor test report will also include an AVISE HCQ test result page.

Image
Sample Test Report

References:

  1. Kao A, Navratil J, Ruffing M, et al. Erythocyte C3d and C4d for Monitoring Disease Activity in Systemic Lupus Erythematosus. Arthritis & Rheumatism. 2010.
  2. Buyon J, et al. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Science and Medicine. 2016.
  3. Merrill J, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science and Medicine. 2018.
  4. Mahler M, Bentow C, O’Malley T, et al. Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus. J Immunol Res. 2017;2017:1720902.
  5. Petri M, Conklin J, Apilado R, et al. Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in SLE [abstract]. Arthritis Rheumatol. 2018
  6. Kao A, McBurney C, Sattar A, et al. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res 2014; 5(4):510-518.
  7. Akhter E, Burlingame R, Seaman A, et al. Anti-C1Q antibodies have a higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2012.
  8. Data on file Exagen, Inc. 2018.